{"disease":{"id":"chordoma","name":"Chordoma","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":1,"pipeline_drug_count":0,"trial_count":6},"drugs":{"marketed":[{"drug_id":"tumor-tissue","indication_name":"Chordoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tumor Tissue","generic_name":"tumor-tissue","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"tumor-tissue","indication_name":"Chordoma, Chondroid","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tumor Tissue","generic_name":"tumor-tissue","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"tumor-tissue","indication_name":"Chordoma, Dedifferentiated","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tumor Tissue","generic_name":"tumor-tissue","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"tumor-tissue","indication_name":"Chordoma, Enchondroid","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tumor Tissue","generic_name":"tumor-tissue","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"tumor-tissue","indication_name":"Chordoma, Myxoid","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tumor Tissue","generic_name":"tumor-tissue","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"tumor-tissue","indication_name":"Chordoma, Not Otherwise Specified","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tumor Tissue","generic_name":"tumor-tissue","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"tumor-tissue","indication_name":"Chordoma, Papillary","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tumor Tissue","generic_name":"tumor-tissue","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"tumor-tissue","indication_name":"Chordoma, Squamous","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tumor Tissue","generic_name":"tumor-tissue","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"tumor-tissue","indication_name":"Chordoma, Squamous with Megakaryoblastic Differentiation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tumor Tissue","generic_name":"tumor-tissue","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"tumor-tissue","indication_name":"Chordoma, Squamous with Rhabdoid Features","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tumor Tissue","generic_name":"tumor-tissue","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"tumor-tissue","indication_name":"Chordoma, Squamous with Spindle Cell Features","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tumor Tissue","generic_name":"tumor-tissue","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"tumor-tissue","indication_name":"Chordoma, Squamous with Undifferentiated Features","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tumor Tissue","generic_name":"tumor-tissue","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"tumor-tissue","indication_name":"Chordoma, Squamous with Undifferentiated Features and Rhabdoid Features","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tumor Tissue","generic_name":"tumor-tissue","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"tumor-tissue","indication_name":"Chordoma, Squamous with Undifferentiated Features and Spindle Cell Features","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tumor Tissue","generic_name":"tumor-tissue","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"tumor-tissue","indication_name":"Chordoma, Squamous with Undifferentiated Features and Undifferentiated Features","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tumor Tissue","generic_name":"tumor-tissue","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"tumor-tissue","indication_name":"Chordoma, Squamous with Undifferentiated Features and Undifferentiated Features and Rhabdoid Features","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tumor Tissue","generic_name":"tumor-tissue","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"tumor-tissue","indication_name":"Chordoma, Squamous with Undifferentiated Features and Undifferentiated Features and Spindle Cell Features","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tumor Tissue","generic_name":"tumor-tissue","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"tumor-tissue","indication_name":"Chordoma, Squamous with Undifferentiated Features and Undifferentiated Features and Undifferentiated Features","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tumor Tissue","generic_name":"tumor-tissue","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"tumor-tissue","indication_name":"Chordoma, Squamous with Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Rhabdoid Features","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tumor Tissue","generic_name":"tumor-tissue","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"tumor-tissue","indication_name":"Chordoma, Squamous with Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Spindle Cell Features","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tumor Tissue","generic_name":"tumor-tissue","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"tumor-tissue","indication_name":"Chordoma, Squamous with Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tumor Tissue","generic_name":"tumor-tissue","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"tumor-tissue","indication_name":"Chordoma, Squamous with Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Rhabdoid Features","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tumor Tissue","generic_name":"tumor-tissue","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"tumor-tissue","indication_name":"Chordoma, Squamous with Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Spindle Cell Features","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tumor Tissue","generic_name":"tumor-tissue","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"tumor-tissue","indication_name":"Chordoma, Squamous with Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tumor Tissue","generic_name":"tumor-tissue","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"tumor-tissue","indication_name":"Chordoma, Squamous with Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Rhabdoid Features","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tumor Tissue","generic_name":"tumor-tissue","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"tumor-tissue","indication_name":"Chordoma, Squamous with Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Spindle Cell Features","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tumor Tissue","generic_name":"tumor-tissue","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"tumor-tissue","indication_name":"Chordoma, Squamous with Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tumor Tissue","generic_name":"tumor-tissue","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"tumor-tissue","indication_name":"Chordoma, Squamous with Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Rhabdoid Features","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tumor Tissue","generic_name":"tumor-tissue","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"tumor-tissue","indication_name":"Chordoma, Squamous with Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Spindle Cell Features","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tumor Tissue","generic_name":"tumor-tissue","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"tumor-tissue","indication_name":"Chordoma, Squamous with Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tumor Tissue","generic_name":"tumor-tissue","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"tumor-tissue","indication_name":"Chordoma, Squamous with Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Rhabdoid Features","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tumor Tissue","generic_name":"tumor-tissue","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"tumor-tissue","indication_name":"Chordoma, Squamous with Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Spindle Cell Features","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tumor Tissue","generic_name":"tumor-tissue","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"tumor-tissue","indication_name":"Chordoma, Squamous with Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tumor Tissue","generic_name":"tumor-tissue","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"tumor-tissue","indication_name":"Chordoma, Squamous with Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Rhabdoid Features","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tumor Tissue","generic_name":"tumor-tissue","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"tumor-tissue","indication_name":"Chordoma, Squamous with Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Spindle Cell Features","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tumor Tissue","generic_name":"tumor-tissue","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"tumor-tissue","indication_name":"Chordoma, Squamous with Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tumor Tissue","generic_name":"tumor-tissue","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"tumor-tissue","indication_name":"Chordoma, Squamous with Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Rhabdoid Features","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tumor Tissue","generic_name":"tumor-tissue","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"tumor-tissue","indication_name":"Chordoma, Squamous with Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Spindle Cell Features","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tumor Tissue","generic_name":"tumor-tissue","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"tumor-tissue","indication_name":"Chordoma, Squamous with Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tumor Tissue","generic_name":"tumor-tissue","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"tumor-tissue","indication_name":"Chordoma, Squamous with Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Rhabdoid Features","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tumor Tissue","generic_name":"tumor-tissue","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"tumor-tissue","indication_name":"Chordoma, Squamous with Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Spindle Cell Features","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tumor Tissue","generic_name":"tumor-tissue","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"tumor-tissue","indication_name":"Chordoma, Squamous with Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tumor Tissue","generic_name":"tumor-tissue","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"tumor-tissue","indication_name":"Chordoma, Squamous with Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Rhabdoid Features","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tumor Tissue","generic_name":"tumor-tissue","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"tumor-tissue","indication_name":"Chordoma, Squamous with Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Spindle Cell Features","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tumor Tissue","generic_name":"tumor-tissue","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"tumor-tissue","indication_name":"Chordoma, Squamous with Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tumor Tissue","generic_name":"tumor-tissue","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"tumor-tissue","indication_name":"Chordoma, Squamous with Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Rhabdoid Features","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tumor Tissue","generic_name":"tumor-tissue","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"tumor-tissue","indication_name":"Chordoma, Squamous with Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Spindle Cell Features","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tumor Tissue","generic_name":"tumor-tissue","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"tumor-tissue","indication_name":"Chordoma, Squamous with Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tumor Tissue","generic_name":"tumor-tissue","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"tumor-tissue","indication_name":"Chordoma, Squamous with Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Rhabdoid Features","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tumor Tissue","generic_name":"tumor-tissue","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"tumor-tissue","indication_name":"Chordoma, Squamous with Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Spindle Cell Features","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tumor Tissue","generic_name":"tumor-tissue","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"tumor-tissue","indication_name":"Chordoma, Squamous with Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tumor Tissue","generic_name":"tumor-tissue","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"tumor-tissue","indication_name":"Chordoma, Squamous with Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Rhabdoid Features","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tumor Tissue","generic_name":"tumor-tissue","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"tumor-tissue","indication_name":"Chordoma, Squamous with Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Undifferentiated Features and Spindle Cell Features","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tumor Tissue","generic_name":"tumor-tissue","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":53,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07005297","title":"Clinical Genetics Branch Eligibility Screening Survey","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":1000,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT02834013","title":"Nivolumab and Ipilimumab in Treating Patients With Rare Tumors","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":818,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04087902","title":"Long-Term Longitudinal QoL in Patients Undergoing EEA","phase":"","overall_status":"RECRUITING","enrollment_count":400,"lead_sponsor_name":"Ohio State University","has_results":false},{"nct_id":"NCT03910465","title":"Children and Adults With Chordoma","phase":"","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT02601950","title":"A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":267,"lead_sponsor_name":"Epizyme, Inc.","has_results":true},{"nct_id":"NCT02838602","title":"Randomized Carbon Ions vs Standard Radiotherapy for Radioresistant Tumors","phase":"NA","overall_status":"RECRUITING","enrollment_count":250,"lead_sponsor_name":"Hospices Civils de Lyon","has_results":false},{"nct_id":"NCT01200680","title":"Genetic Clues to Chordoma Etiology: A Protocol to Identify Sporadic Chordoma Patients for Studies of Cancer-Susceptibility Genes","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":188,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT02936102","title":"A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":154,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT00919269","title":"Collecting and Storing Tissue, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Soft Tissue Sarcoma","phase":"","overall_status":"COMPLETED","enrollment_count":150,"lead_sponsor_name":"Children's Oncology Group","has_results":false},{"nct_id":"NCT03058289","title":"A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":111,"lead_sponsor_name":"Intensity Therapeutics, Inc.","has_results":true},{"nct_id":"NCT06029218","title":"Analysis of the Toxicity and Efficacy of Daily 1 vs 2 Beam Proton Therapy","phase":"NA","overall_status":"RECRUITING","enrollment_count":106,"lead_sponsor_name":"Centre Antoine Lacassagne","has_results":false},{"nct_id":"NCT02986516","title":"Sacral Chordoma: Surgery Versus Definitive Radiation Therapy in Primary Localized Disease","phase":"NA","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Italian Sarcoma Group","has_results":false},{"nct_id":"NCT05707767","title":"A Prospective Study of Surgical Treatment Strategies for Chordoma","phase":"NA","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Xuanwu Hospital, Beijing","has_results":false},{"nct_id":"NCT05286801","title":"Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":86,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05033288","title":"Comparing Carbon Ion Therapy, Surgery, and Proton Therapy for Management of Pelvic Sarcomas Involving the Bone","phase":"","overall_status":"RECRUITING","enrollment_count":72,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT02802969","title":"Improvement of Local Control in Skull Base, Spine and Sacral Chordomas Treated by Surgery and Protontherapy Targeting Hypoxic Cells Revealed by [18F]FAZA) PET/CT Tracers","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":64,"lead_sponsor_name":"Institut Curie","has_results":false},{"nct_id":"NCT06535997","title":"Descriptive Cohort of French Patients Treated With Carbonetherapy Since October 2010 Outside PHRC-ETOILE","phase":"","overall_status":"COMPLETED","enrollment_count":62,"lead_sponsor_name":"Hospices Civils de Lyon","has_results":false},{"nct_id":"NCT04042597","title":"Anlotinib Hydrochloride Versus Imatinib Mesylate in Locally Advanced, Unresectable or Metastatic Chordoma","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":60,"lead_sponsor_name":"Peking University People's Hospital","has_results":false},{"nct_id":"NCT00341627","title":"Genetic Aspects of Chordoma: A Collaboration With SEER Registries to Identify Chordoma Families","phase":"","overall_status":"COMPLETED","enrollment_count":56,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT00410670","title":"Chordoma Family Study","phase":"","overall_status":"COMPLETED","enrollment_count":55,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05407441","title":"Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":49,"lead_sponsor_name":"Susan Chi, MD","has_results":false},{"nct_id":"NCT03083678","title":"Afatinib in Locally Advanced and Metastatic Chordoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":43,"lead_sponsor_name":"Leiden University Medical Center","has_results":false},{"nct_id":"NCT03110744","title":"CDK4/6 Inhibition in Locally Advanced/Metastatic Chordoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":43,"lead_sponsor_name":"University Hospital Heidelberg","has_results":false},{"nct_id":"NCT04486820","title":"Immunohistochemical Study of Chordomas to Improve Their Diagnosis and Prognosis Care","phase":"","overall_status":"COMPLETED","enrollment_count":40,"lead_sponsor_name":"Centre Hospitalier Universitaire de Saint Etienne","has_results":false},{"nct_id":"NCT03242382","title":"Trial of Palbociclib in Second Line of Advanced Sarcomas With CDK4 Overexpression.","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":40,"lead_sponsor_name":"Grupo Espanol de Investigacion en Sarcomas","has_results":false},{"nct_id":"NCT04246671","title":"TAEK-VAC-HerBy Vaccine for Brachyury and HER2 Expressing Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":37,"lead_sponsor_name":"Bavarian Nordic","has_results":false},{"nct_id":"NCT05888064","title":"Multi-parametric Imaging in Personalized Radiotherapy","phase":"","overall_status":"RECRUITING","enrollment_count":35,"lead_sponsor_name":"CNAO National Center of Oncological Hadrontherapy","has_results":false},{"nct_id":"NCT03190174","title":"Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":34,"lead_sponsor_name":"Sarcoma Oncology Research Center, LLC","has_results":true},{"nct_id":"NCT06140732","title":"Apatinib Combined With Camrelizumab in Treating Participants With Advanced Chordoma","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"Xuanwu Hospital, Beijing","has_results":false},{"nct_id":"NCT03595228","title":"BN Brachyury and Radiation in Chordoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":29,"lead_sponsor_name":"Bavarian Nordic","has_results":true},{"nct_id":"NCT05041127","title":"Cetuximab for the Treatment of Advanced Unresectable or Metastatic Chordoma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":29,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT02383498","title":"QUILT-3.011 Phase 2 Yeast-Brachyury Vaccine Chordoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":24,"lead_sponsor_name":"NantCell, Inc.","has_results":true},{"nct_id":"NCT05861245","title":"Hypofractionated Protontherapy in Chordomas and Chondrosarcomas of the Skull Base","phase":"NA","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"Quironsalud","has_results":false},{"nct_id":"NCT05519917","title":"Study to Evaluate the Efficacy of Afatinib in Skull Base Chordoma","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":20,"lead_sponsor_name":"Huashan Hospital","has_results":false},{"nct_id":"NCT00496119","title":"Proton Beam Therapy for Chordoma Patients","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":19,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT03955042","title":"Pemetrexed for the Treatment of Chordoma","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":15,"lead_sponsor_name":"Saint John's Cancer Institute","has_results":false},{"nct_id":"NCT03623854","title":"Nivolumab and Relatlimab in Treating Participants With Advanced Chordoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":10,"lead_sponsor_name":"Jonsson Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT03647423","title":"QUILT-3.091 NANT Chordoma Vaccine vs Radiation in Subjects With Unresectable Chordoma.","phase":"PHASE1, PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"ImmunityBio, Inc.","has_results":false},{"nct_id":"NCT04091295","title":"BLESSED: Expanded Access for DNG64-CAR-V for Advanced Pancreatic Cancer, Sarcoma and Carcinoma of Breast","phase":"","overall_status":"AVAILABLE","enrollment_count":null,"lead_sponsor_name":"Aveni Foundation","has_results":false},{"nct_id":"NCT03874455","title":"Tazemetostat Expanded Access Program for Adults With Solid Tumors","phase":"","overall_status":"NO_LONGER_AVAILABLE","enrollment_count":null,"lead_sponsor_name":"Epizyme, Inc.","has_results":false}],"total":40},"guidelines":[],"source":"Drug Landscape verified database"}